Shares of InflaRx N.V. (NASDAQ:IFRX – Get Free Report) have been given an average recommendation of “Moderate Buy” by the seven research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $7.00.
A number of equities research analysts recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of InflaRx in a research note on Wednesday, June 24th. Guggenheim restated a “buy” rating and set a $14.00 target price on shares of InflaRx in a research report on Tuesday, April 21st. Cantor Fitzgerald upped their price target on InflaRx from $2.00 to $4.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Oppenheimer began coverage on shares of InflaRx in a research report on Friday, April 24th. They issued an “outperform” rating and a $5.00 price target on the stock. Finally, Wall Street Zen upgraded shares of InflaRx from a “sell” rating to a “hold” rating in a report on Saturday, May 9th.
Check Out Our Latest Research Report on IFRX
InflaRx Stock Down 0.5%
InflaRx (NASDAQ:IFRX – Get Free Report) last released its earnings results on Wednesday, May 6th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.08. On average, analysts predict that InflaRx will post -0.33 earnings per share for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in IFRX. Bank of America Corp DE bought a new position in shares of InflaRx during the 3rd quarter valued at about $3,316,000. Suvretta Capital Management LLC increased its position in shares of InflaRx by 22.4% during the fourth quarter. Suvretta Capital Management LLC now owns 7,933,910 shares of the company’s stock worth $8,013,000 after acquiring an additional 1,450,000 shares in the last quarter. 683 Capital Management LLC increased its position in shares of InflaRx by 47.3% during the fourth quarter. 683 Capital Management LLC now owns 3,315,000 shares of the company’s stock worth $3,348,000 after acquiring an additional 1,065,000 shares in the last quarter. Woodline Partners LP acquired a new stake in shares of InflaRx during the first quarter worth $766,000. Finally, Adage Capital Partners GP L.L.C. acquired a new stake in shares of InflaRx during the second quarter worth $262,000. 42.39% of the stock is currently owned by institutional investors.
InflaRx Company Profile
InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.
Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.
Read More
- Five stocks we like better than InflaRx
- 3 Rare-Earth ETFs That Help Investors Balance Exposure and Risk
- Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs
- Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing
- This Dividend ETF Choice Could Shape Your Income Strategy Through 2026
Receive News & Ratings for InflaRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InflaRx and related companies with MarketBeat.com's FREE daily email newsletter.
